Acelity falls to 3M, but the conglomerate has taken on a great deal of debt and could see its credit rating fall.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Big medtech is keeping its purse-strings closed – but private equity sees value in subsidiaries.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
Big cap medtech is hiring, largely thanks to organic growth.
A return to tuck-in deals – sort of.